Valeant Pharmaceuticals International (VRX) - FREE Research Report

Kornwasser Laizer who is EVP, Company Group Chairman at Valeant Pharmaceuticals International bought 3,500 shares at $107.38 on Nov. 20, 2013. Following this transaction, the EVP, Company Group Chairman owned 16,500 shares meaning that the stake was reduced by 26.92% with the 3,500 share transaction.

The shares most recently traded at $108.23, up $0.85, or 0.78% since the insider transaction. Historical insider transactions for Valeant Pharmaceuticals International go as follows:

  • 4-Week # shares bought: 1,500
  • 4-Week # shares sold: 5,000
  • 12-Week # shares bought: 53,500
  • 12-Week # shares sold: 14,000
  • 24-Week # shares bought: 71,972
  • 24-Week # shares sold: 20,000

The average volume for Valeant Pharmaceuticals International has been 1.1 million shares per day over the past 30 days. Valeant Pharmaceuticals International has a market cap of $35.4 billion and is part of the health care sector and drugs industry. Shares are up 78.28% year to date as of the close of trading on Wednesday.

Valeant Pharmaceuticals International, Inc., a specialty pharmaceutical company, develops, manufactures, and markets pharmaceutical products and medical devices in the areas of neurology, dermatology, and branded generics. The stock currently has a dividend yield of 0.95%. Currently there are 8 analysts that rate Valeant Pharmaceuticals International a buy, 1 analyst rates it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on VRX - FREE

TheStreet Quant Ratings rates Valeant Pharmaceuticals International as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and generally higher debt management risk. Get the full Valeant Pharmaceuticals International Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Insider Trading Alert - LOCK, CYBX And EGLT Traded By Insiders

Insider Trading Alert - CYBX, MRD And FB Traded By Insiders

Insider Trading Alert - CYBX, STAG And TBNK Traded By Insiders

Insider Trading Alert - CYBX, KAMN And FRED Traded By Insiders

That Was the Week That Was